Natera Inc (NASDAQ:NTRA) Receives $42.40 Consensus PT from Brokerages

Natera Inc (NASDAQ:NTRA) has been given a consensus rating of “Buy” by the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $42.40.

A number of analysts have recently issued reports on NTRA shares. ValuEngine downgraded shares of Natera from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. JPMorgan Chase & Co. increased their target price on Natera from $27.00 to $32.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Cowen increased their target price on Natera from $30.00 to $42.00 and gave the company an “average” rating in a research note on Friday, October 18th. Zacks Investment Research downgraded Natera from a “buy” rating to a “hold” rating in a research report on Tuesday, November 12th. Finally, Craig Hallum lifted their price target on Natera from $37.00 to $49.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th.

In other news, COO Robert Alan Schueren sold 12,545 shares of the firm’s stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $33.19, for a total transaction of $416,368.55. Following the transaction, the chief operating officer now directly owns 25,000 shares of the company’s stock, valued at $829,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 1,206 shares of Natera stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $29.50, for a total value of $35,577.00. Following the completion of the transaction, the chief financial officer now owns 17,211 shares in the company, valued at approximately $507,724.50. The disclosure for this sale can be found here. Insiders have sold 63,854 shares of company stock worth $2,231,769 over the last quarter. Company insiders own 9.29% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. TD Asset Management Inc. bought a new position in Natera during the 2nd quarter worth approximately $477,000. Cubist Systematic Strategies LLC boosted its position in Natera by 44.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 36,381 shares of the medical research company’s stock valued at $1,003,000 after buying an additional 11,221 shares during the period. Asymmetry Capital Management L.P. grew its holdings in Natera by 615.4% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 217,899 shares of the medical research company’s stock worth $6,010,000 after acquiring an additional 187,441 shares during the last quarter. Allianz Asset Management GmbH grew its holdings in Natera by 4.5% in the 2nd quarter. Allianz Asset Management GmbH now owns 589,036 shares of the medical research company’s stock worth $16,246,000 after acquiring an additional 25,334 shares during the last quarter. Finally, Mackay Shields LLC bought a new stake in Natera in the 3rd quarter worth $1,436,000. 85.14% of the stock is owned by institutional investors.

NTRA traded down $0.08 on Friday, reaching $36.64. The company had a trading volume of 5,671 shares, compared to its average volume of 618,097. The business has a 50 day simple moving average of $38.07 and a 200 day simple moving average of $31.07. The company has a market cap of $2.85 billion, a price-to-earnings ratio of -17.12 and a beta of 1.40. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.26 and a current ratio of 2.35. Natera has a 52-week low of $11.08 and a 52-week high of $40.92.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, November 6th. The medical research company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.20. The business had revenue of $77.90 million during the quarter, compared to analysts’ expectations of $73.97 million. Natera had a negative net margin of 42.45% and a negative return on equity of 252.79%. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.49) EPS. As a group, equities research analysts predict that Natera will post -2.15 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Further Reading: Why is the Consumer Price Index (CPI) important?

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.